Patents by Inventor Ming-Fong Lin

Ming-Fong Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostate cancer cell lines
    Patent number: 7238524
    Abstract: Novel human prostate cancer-associated neuroendocrine (NE)-like cell lines are provided that were derived via a process that resembles clinical androgen ablation therapy for advanced prostate cancer.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: July 3, 2007
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Ming Fong Lin
  • Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
    Publication number: 20060294615
    Abstract: Presented is a therapeutic method to treat prostate carcinomas in mammals comprising the administration of cellular PAcP protein. Also presented is a method to diagnose androgen-insensitive prostate carcinomas by determining the expression level of cellular PAcP in the prostate carcinomas, a decrease in expression being indicative of androgen-insensitivity. A promoter region that is specifically expressed in prostate tissue is presented, as is a xenograft animal model that mimics human prostate carcinomas in the expression of cellular PAcP.
    Type: Application
    Filed: August 21, 2006
    Publication date: December 28, 2006
    Inventor: Ming-Fong Lin
  • Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
    Patent number: 7094533
    Abstract: Presented is a therapeutic method to treat prostate carcinomas in mammals comprising the administration of cellular PAcP protein. Also presented is a method to diagnose androgen-insensitive prostate carcinomas by determining the expression level of cellular PAcP in the prostate carcinomas, a decrease in expression being indicative of androgen-insensitivity. A promoter region that is specifically expressed in prostate tissue is presented, as is a xenograft animal mode that mimics human prostate carcinomas in the expression of cellular PAcP.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: August 22, 2006
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Ming-Fong Lin
  • Novel prostate cancer cell lines
    Publication number: 20050014209
    Abstract: Novel human prostate cancer-associated neuroendocrine (NE)-like cell lines are provided that were derived via a process that resembles clinical androgen ablation therapy for advanced prostate cancer.
    Type: Application
    Filed: June 7, 2004
    Publication date: January 20, 2005
    Inventor: Ming-Fong Lin
  • Prostate cancer cell lines
    Patent number: 6777230
    Abstract: Novel human prostate cancer-associated neuroendocrine (NE)-like cell lines are provided that were derived via a process that resembles clinical androgen ablation therapy for advanced prostate cancer.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: August 17, 2004
    Assignee: Board of Regents of the University of Nebraska
    Inventor: Ming-Fong Lin
  • Novel prostate cancer cell lines
    Publication number: 20030027227
    Abstract: Novel human prostate cancer-associated neuroendocrine (NE)-like cell lines are provided that were derived via a process that resembles clinical androgen ablation therapy for advanced prostate cancer.
    Type: Application
    Filed: July 31, 2001
    Publication date: February 6, 2003
    Inventor: Ming-Fong Lin